BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical technology company’s stock.

Other research analysts have also issued reports about the stock. Benchmark restated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research report on Wednesday, October 2nd. Ascendiant Capital Markets lowered their target price on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

BIOLASE Price Performance

NASDAQ BIOL opened at $0.01 on Wednesday. The stock has a market capitalization of $167,035.00, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94. The firm has a 50-day moving average price of $0.02 and a 200 day moving average price of $0.07.

Institutional Trading of BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC increased its position in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 as of its most recent filing with the SEC. 8.79% of the stock is owned by hedge funds and other institutional investors.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.